What is Flyte?
Flyte, developed by Pelvital USA, operates at the intersection of health-tech and clinical medicine. The company specializes in innovative pelvic floor therapy solutions, specifically targeting stress urinary incontinence through its flagship intravaginal device. By leveraging mechanotherapy, Flyte provides a non-invasive, evidence-based alternative to traditional surgical interventions. The platform is further bolstered by a digital ecosystem, including a supportive mobile application and direct access to pelvic health experts, ensuring a comprehensive treatment experience for patients seeking improved bladder control and cellular healing. This integrated approach positions Flyte as a significant player in the burgeoning women's health technology market, where demand for convenient, clinically validated home-care solutions continues to rise.
How much funding has Flyte raised?
Flyte has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2024): $5M with participation from Wisconsin Investment Partners, Boomerang Ventures, Blue Pacific Fund, VisionTech Partners, Pier 70 Ventures, and Life Science Angels
Key Investors in Flyte
Wisconsin Investment Partners
Wisconsin Investment Partners is a prominent angel investment group and business incubator that provides essential capital and operational support to early-stage ventures.
Boomerang Ventures
Boomerang Ventures is a specialized venture studio and fund focused on connected health technologies, guiding medical device innovations from ideation to commercialization.
VisionTech Partners
VisionTech Partners is a Midwest-based angel network that conducts rigorous due diligence to identify and fund high-potential startups within the early-growth ecosystem.
What's next for Flyte?
With this major enterprise-level funding, Flyte is poised to transition from its current growth phase into a broader commercial expansion. The strategic allocation of capital will likely focus on enhancing clinical research initiatives, refining the digital user experience, and scaling distribution channels to meet the increasing demand for accessible pelvic health interventions. As the company matures, the focus will shift toward solidifying its market position as a leader in tech-enabled medical devices, potentially exploring new therapeutic applications for its proprietary mechanotherapy technology. By maintaining its commitment to rigorous clinical standards and patient-centric design, Flyte is set to redefine the standard of care for urinary incontinence, driving long-term value for both its stakeholders and the patients it serves.
See full Flyte company page
